Form 8-K - Current report:
SEC Accession No. 0001714899-20-000091
Filing Date
2020-08-07
Accepted
2020-08-07 16:43:50
Documents
16
Period of Report
2020-08-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dnli-20200807.htm   iXBRL 8-K 51819
2 EX-99.1 ex991pressreleaseq22020.htm EX-99.1 129088
8 denalitlogo0111.jpg GRAPHIC 65449
  Complete submission text file 0001714899-20-000091.txt   422386

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20200807.xsd EX-101.SCH 2453
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dnli-20200807_cal.xml EX-101.CAL 730
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnli-20200807_def.xml EX-101.DEF 1663
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20200807_lab.xml EX-101.LAB 23970
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20200807_pre.xml EX-101.PRE 12666
9 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20200807_htm.xml XML 10815
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 201085446
SIC: 2836 Biological Products, (No Diagnostic Substances)